A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Ruperto, N; Murray, KJ; Gerloni, V; Wulffraat, N; de Oliveira, SKF; Falcini, F; Dolezalova, P; Alessio, M; Burgos-Vargas, R; Corona, F; Vesely, R; Foster, H; Davidson, J; Zulian, F; Asplin, L; Baildam, E; Consuegra, JG; Ozdogan, H; Saurenmann, R; Joos, R; Pistorio, A; Woo, P; Martini, A

doi:10.1002/art.20288

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Copy For Citation

Ruperto N., Murray K., Gerloni V., Wulffraat N., de Oliveira S., Falcini F., ...More

ARTHRITIS AND RHEUMATISM, vol.50, no.7, pp.2191-2201, 2004 (SCI-Expanded)

Publication Type: Article / Article
Volume: 50 Issue: 7
Publication Date: 2004
Doi Number: 10.1002/art.20288
Journal Name: ARTHRITIS AND RHEUMATISM
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2191-2201
Istanbul University Affiliated: No

Abstract

Objective. To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15mg/m(2)/week) versus a higher dosage (30 mg/m(2)/ week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/ week).